Patient Device Preference for Home Hemodialysis: A Subset Analysis of the Tablo Home IDE Trial

Yaadveer Chahal, BSc1, Troy Plumb, MD2, Michael Aragon, MD1
1 Outset Medical, San Jose, CA; 2 University of Nebraska Medical Center, Omaha, NE

BACKGROUND:
- Home hemodialysis (HD) is in critical need of new technology to facilitate its delivery, as evidenced by the recent Advancing American Kidney Health Initiative.
- The Tablo® Hemodialysis System is the first new technology to seek expansion into home use in nearly 15 years.
- Tablo is designed to simplify patient self-care through automation, a simplified user interface, integrated water purification and on demand dialysate production.

OBJECTIVE:
- To evaluate device preference of prior In-Home hemodialysis patients in the Tablo home investigational device exemption (IDE) trial.

RESULTS:
- Thirteen of the 30 participants in the IDE trial were performing In-Home HD at the time of enrollment.
- Prior to trial, prescriptions averaged 4.5 per week with an average time of 3.1 hours per treatment.
- Trial prescriptions were for 4 days per week and an average of 3.4 hours per treatment.

CONCLUSION:
- Participants in the Tablo Home IDE with previous Home HD experience preferred Tablo compared to their prior device across every dimension.
- With its patient-centric design, on demand water purification and intuitive user interface, Tablo provides a new option for expanding home dialysis in the United States, aligning with ambitious targets recently set by policymakers.

CONTACT FOR CORRESPONDENCE:
Michael Aragon, MD· maragon@outsetmedical.com

FIGURES 1 & 2
Study parameters

FIGURE 3
Tablo preference

OVERALL EASE OF USE 86%
USER FLEXIBILITY 76%
EASE OF SALINE BOLUS APPLICATION 78%
MANAGEMENT OF DIALYSIS SUPPLIES 81%
MACHINE CLEAN-UP AND GENERAL CARE 84%
TREATMENT TAKE-DOWN 84%
ADAPTABILITY INTO YOUR HOME ENVIRONMENT 84%
ALARM TROUBLESHOOTING 85%
TREATMENT SET-UP 86%
SYSTEM SIMPLICITY OF TRAINING TOOLS 89%
TOUCHSCREEN 100%